Cardiovascular Therapeutics

Most influential

• Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease
  Marc Steven Sabatine, Robert Patrick Giugliano, ANTHONY C. KEECH et al. · 2017 · New England Journal of Medicine
  Article6,134 citationsdoi:10.1056/nejmoa1615664
• Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel
  Brian A. Ference, Henry N. Ginsberg, Ian M Graham et al. · 2017 · European Heart Journal
  Article3,961 citationsdoi:10.1093/eurheartj/ehx144
• Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome
  Gregory G. Schwartz, Philippe Gabríel Steg, Michael J. Szarek et al. · 2018 · New England Journal of Medicine
  Article3,628 citationsdoi:10.1056/nejmoa1801174
• Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia
  Deepak L. Bhatt, Philippe Gabríel Steg, Michael J. Miller et al. · 2018 · New England Journal of Medicine
  Article3,316 citationsdoi:10.1056/nejmoa1812792
• Efficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular Events
  Jennifer G. Robinson, Michel Farnier, Michel Krempf et al. · 2015 · New England Journal of Medicine
  Article2,295 citationsdoi:10.1056/nejmoa1501031
• Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement
  Florian Kronenberg, Samia Mora, Erik S.G. Stroes et al. · 2022 · European Heart Journal
  Article1,448 citationsdoi:10.1093/eurheartj/ehac361
• Association Between Lowering LDL-C and Cardiovascular Risk Reduction Among Different Therapeutic Interventions
  Michael G. Silverman, Brian A. Ference, Kyungah Im et al. · 2016 · JAMA
  Review1,482 citationsdoi:10.1001/jama.2016.13985
• Long-term efficacy and safety of inclisiran in patients with high cardiovascular risk and elevated LDL cholesterol (ORION-3): results from the 4-year open-label extension of the ORION-1 trial
  Ray KK, Troquay RPT, Visseren FLJ et al. · 2023 · The lancet. Diabetes & endocrinology

  Introduction Whether long-term treatment with the twice-yearly, siRNA therapeutic inclisiran, which reduces hepatic production of proprotein convertase subtilisin/kexin type 9 (PCSK9), results in sustained reductions in LDL cholesterol with an acceptable safety profile is not known. The aim of this study was to assess the effect of long-term dosing of inclis…

  Abstract excerpt by Ray KK et al., CC-BY, https://doi.org/10.1016/s2213-8587(22)00353-9; truncated.

  Article257 citationsdoi:10.1016/s2213-8587(22)00353-9
• Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management
  M. John Chapman, Henry N. Ginsberg, Pierre Amarenco et al. · 2011 · European Heart Journal
  Review1,227 citationsdoi:10.1093/eurheartj/ehr112
• Targeting proprotein convertase subtilisin/kexin type 9 (PCSK9): from bench to bedside
  Bao X, Liang Y, Chang H et al. · 2024 · Signal transduction and targeted therapy

  Proprotein convertase subtilisin/kexin type 9 (PCSK9) has evolved as a pivotal enzyme in lipid metabolism and a revolutionary therapeutic target for hypercholesterolemia and its related cardiovascular diseases (CVD). This comprehensive review delineates the intricate roles and wide-ranging implications of PCSK9, extending beyond CVD to emphasize its signific…

  Abstract excerpt by Bao X et al., CC-BY, https://doi.org/10.1038/s41392-023-01690-3; truncated.

  Review145 citationsdoi:10.1038/s41392-023-01690-3
• A Test in Context: Lipoprotein(a)
  Sotirios Tsimikas · 2017 · Journal of the American College of Cardiology
  Review1,136 citationsdoi:10.1016/j.jacc.2016.11.042
• Lipoprotein(a) Reduction in Persons with Cardiovascular Disease
  Sotirios Tsimikas, Ewa Karwatowska‐Prokopczuk, Ioanna Gouni‐Berthold et al. · 2020 · New England Journal of Medicine
  Article1,090 citationsdoi:10.1056/nejmoa1905239
• Triglyceride-rich lipoproteins and their remnants: metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies—a consensus statement from the European Atherosclerosis Society
  Henry N. Ginsberg, Chris J. Packard, M. John Chapman et al. · 2021 · European Heart Journal
  Article978 citationsdoi:10.1093/eurheartj/ehab551
• American Association of Clinical Endocrinologists and American College of Endocrinology Guidelines for Management of Dyslipidemia and Prevention of Cardiovascular Disease
  Paul S. Jellinger, Yehuda Handelsman, Paul D. Rosenblit et al. · 2017 · Endocrine Practice
  Article1,093 citationsdoi:10.4158/ep171764.appgl
• 2021 Canadian Cardiovascular Society Guidelines for the Management of Dyslipidemia for the Prevention of Cardiovascular Disease in Adults
  Glen J. Pearson, George Thanassoulis, Todd J. Anderson et al. · 2021 · Canadian Journal of Cardiology
  Article848 citationsdoi:10.1016/j.cjca.2021.03.016

Newest work

• Effectiveness and safety of target-specific RNA-based lipid-lowering therapies: A systematic review and meta-analysis of randomized controlled trials
  Widjaja JS, Adji AS, Baraja A et al. · 2026 · European journal of pharmacology
  Reviewdoi:10.1016/j.ejphar.2026.179420
• Lipoprotein(a) reduction with PCSK9-targeting pharmacotherapy: A prospective real-world registry study
  Kafol J, Fras Z, Novakovic M et al. · 2026 · Atherosclerosis
  Articledoi:10.1016/j.atherosclerosis.2026.121…
• Simulation and Analysis of Solute Transport in Multi-Lymphangion Lymphatic Vessels
  Timo Jakumeit, Thiha Aung, Robert Schober et al. · 2026
  PreprintarXiv:2609.25964
• Serial Coronary Plaque Composition After Inclisiran Initiation Assessed by Automated CCTA: A Retrospective Pilot Study
  Kawada K, Suzuki M, Mochizuki J et al. · 2026 · Diagnostics (Basel, Switzerland)
  Articledoi:10.3390/diagnostics16183009
• The 2026 ACC/AHA Dyslipidemia Guideline: A Critical and Transatlantic Perspective on Personalized Lipid Management
  Sabouret P, Mafrica D, Giamundo DM et al. · 2026 · Life (Basel, Switzerland)
  Reviewdoi:10.3390/life16091470
• Prediction of inclisiran efficacy in patients with established atherosclerotic cardiovascular disease: the SIRIUS in-silico modelling of cardiovascular outcomes
  Angoulvant D, Peyronnet E, Cariou B et al. · 2026 · European journal of preventive cardiology
  Article6 citationsdoi:10.1093/eurjpc/zwaf783
• The Utilization of Inclisiran for the Optimization of Lipid Management in People Living with HIV: A Clinical Case Series and Comprehensive Review
  Petrakis V, Panopoulou M, Grapsa A et al. · 2026 · Reports (MDPI)
  Articledoi:10.3390/reports9030284
• A New Option for the Management of Dyslipidemias: Advances in Research on the Small Interfering RNA Drug Inclisiran
  Wu X, Zhang J · 2026 · Reviews in cardiovascular medicine
  Reviewdoi:10.31083/rcm48237
• Inclisiran-induced LDL-cholesterol reduction with and without concomitant statin therapy: a real-world analysis
  Seidel M, Seibert FS, Anft M et al. · 2026 · BMC cardiovascular disorders
  Articledoi:10.1186/s12872-026-06429-w
• HPS-4/TIMI 65/ORION-4: A double-blind randomized placebo-controlled trial assessing the effects of inclisiran on clinical outcomes among people with atherosclerotic cardiovascular disease: Trial design, recruitment, and baseline characteristics
  Mafham MM, Zayed MG, Collins R et al. · 2026 · American heart journal
  Article16 citationsdoi:10.1016/j.ahj.2026.107546

Clinical trials

• A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a)
  Eli Lilly and Company · 2024 · ClinicalTrials.gov
  Clinical trialNCT06292013
• OCEAN(a)-PreEvent - Olpasiran Trials of Cardiovascular Events And LipoproteiN(a) Reduction to Prevent First Major Cardiovascular Events
  Amgen · 2025 · ClinicalTrials.gov
  Clinical trialNCT07136012
• Study of Inclisiran to Prevent Cardiovascular (CV) Events in Participants With Established Cardiovascular Disease
  Novartis Pharmaceuticals · 2021 · ClinicalTrials.gov
  Clinical trialNCT05030428
• An Open Label Extension (OLE) Study (Following Completion of CTQJ230A12301) to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230)
  Novartis Pharmaceuticals · 2026 · ClinicalTrials.gov
  Clinical trialNCT07517263
• A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.
  Novartis Pharmaceuticals · 2023 · ClinicalTrials.gov
  Clinical trialNCT05739383
• A Randomized Trial Assessing the Effects of Inclisiran on Clinical Outcomes Among People With Cardiovascular Disease
  University of Oxford · 2018 · ClinicalTrials.gov
  Clinical trialNCT03705234
• Cardiovascular Outcome Study to Evaluate the Effect of Obicetrapib in Patients With Cardiovascular Disease
  NewAmsterdam Pharma · 2022 · ClinicalTrials.gov
  Clinical trialNCT05202509
• Olpasiran Trials of Cardiovascular Events and Lipoprotein(a) Reduction (OCEAN(a)) - Outcomes Trial
  Amgen · 2022 · ClinicalTrials.gov
  Clinical trialNCT05581303

Full ranked list (JSON) →